Methylphenidate-Induced Raynaud’s Phenomenon In Two Cases With Attention-Deficit/Hyperactivity Disorder
| Autor: | Hurşit Ferahkaya, Ömer Faruk Akça |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Methylphenidate business.industry metilfenidat Raynaud fenomeni DEHB Geography Planning and Development Management Monitoring Policy and Law medicine.disease methylphenidate Raynaud’s phenomenon ADHD Health Care Sciences and Services Phenomenon medicine Attention deficit hyperactivity disorder Sağlık Bilimleri ve Hizmetleri Psychiatry business medicine.drug |
| Zdroj: | Volume: 11, Issue: 3 423-424 Journal of Contemporary Medicine |
| ISSN: | 2667-7180 |
| DOI: | 10.16899/jcm.837023 |
| Popis: | Attention-deficit/hyperactivity disorder is a common neurodevelopmental disorder in childhood, for which there are several different treatment options. Among the suggested medications, methylphenidate (a central nervous system stimulant) is the first option in the treatment of ADHD. Psychostimulants are associated with various vascular problems including peripheral vasculopathy. This report describes two patients with ADHD who developed Raynaud's phenomenon during the modified-release methylphenidate treatment. Dikkat eksikliği / hiperaktivite bozukluğu, çocukluk çağında çok sayıda farklı tedavi seçeneği bulunan yaygın bir nörogelişimsel bozukluktur. Önerilen ilaçlar arasında metilfenidat (bir santral sinir sistemi stimülasyonu) DEHB tedavisinde ilk seçenektir. Psikostimülanlar, periferik vaskülopati dahil olmak üzere çeşitli vasküler problemlerle ilişkilidir. Bu raporda, modifiye salınımlı metilfenidat tedavisi sırasında Raynaud fenomeni geliştiren iki DEHB hastası sunulmaktadır. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|